ClinicalTrials.gg
CompletedNCT01109069Updated May 27, 2020Results posted

Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

A Phase 2 interventional study of PCI-32765 in B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and Diffuse Well-differentiated Lymphocytic Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-27.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
199
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
16th of 83
199 · median 44
Started
2010
with 2 others
Phase 2
43 of 83
6 open now
Registered
2nd of 83
by date
Lead sponsor
10 of 83
Pharmacyclics LLC.

Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 16th largest by enrollment, is one of 3 that started in 2010, is one of 43 in phase 2, and was the 2nd registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,038 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to determine the long-term safety of a fixed-dose, daily regimen of PCI-32765 PO in subjects with B cell lymphoma or chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).

03

Conditions studied

  • B-cell Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Diffuse Well-differentiated Lymphocytic Lymphoma
  • B Cell Lymphoma
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Non-Hodgkin's Lymphoma
  • Waldenstrom Macroglobulinemia
  • Burkitt Lymphoma
  • B-Cell Diffuse Lymphoma

Keywords

  • PCI-32765
  • Lymphoma, B-Cell
  • Leukemia, Lymphoid
  • Leukemia, B-Cell
  • Bruton's Tyrosine Kinase
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women with recurrent surface immunoglobulin positive B cell non-Hodgkin's lymphoma (NHL) according to WHO classification (including, but not limited to, CLL/SLL, Waldenström's macroglobulinemia [WM], mantle cell lymphoma [MCL], and diffuse large B cell lymphoma [DLBCL) who have met requirements for roll over from their parent protocol and want to continue study drug.
  • Female subjects of must have a negative serum or urine pregnancy test within 3 days of the first dose of study drug and agree to use dual methods of during the study and for 1 month following the last dose with study drug. Post menopausal females (>45 years old and without menses for >1 year) and surgically sterilized females are exempt from this criterion.
  • Male subjects must use an effective barrier method of contraception during the study and for 3 months following the last dose if sexually active with a female of childbearing potential.
  • Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty
  • Ability to understand the purpose and risks of the study and provide signed and dated and authorization to use protected health information (in accordance with national and local patient privacy regulations).

Exclusion criteria

Exclusion Criteria:

  • A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of PCI-32765 PO, or put the study outcomes at undue risk
  • Known history of (HIV) or active infection with Virus (HCV) or Virus (HBV) or any uncontrolled active systemic infection.
  • Lactating or pregnant
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
199 participants (actual)

Study arms

  • Experimental
    PCI-32765

    Drug: PCI-32765

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Adverse Events

    Subjects were to receive ibrutinib once daily at the dose level the subject was receiving in the parent study until disease progression or unacceptable toxicity. The study included Screening, Treatment (from the first dose until study drug discontinuation), and Follow-up Phases.

    Time frame: 30 days after last dose of study drug, continue up to 6 months

Secondary outcomes

  1. Progressive Disease (PD)

    A progressive disease confirmed by a CT scan.

    Time frame: 30 days after last dose of study drug, continue up to 6 months

  2. Death Event

    All death events are due to AE, progressive disease, and other reasons.

    Time frame: 30 days after last dose of study drug

  3. Documented Responses

    Investigator-assessed responses were summarized descriptively for subjects with CLL/SLL and listed for subjects with other NHLs based on the efficacy population.

    Time frame: 30 days after last dose of study drug, continue up to 6 months

07

Results

Posted May 7, 2020

Participant flow

27 July 2010 (the first Patient enrolled) to 31 March 2016 (the Last patient enrolled), Study was approved on June 2010.

Participant flow — Overall Study
MilestoneA LONG-TERM SAFETY STUDY OF BRUTON'S TYROSINE KINASE (BTK) INH
Started199
Completed106
Not completed93

Outcome measures

PrimaryNumber of Subjects With Adverse Events

Subjects were to receive ibrutinib once daily at the dose level the subject was receiving in the parent study until disease progression or unacceptable toxicity. The study included Screening, Treatment (from the first dose until study drug discontinuation), and Follow-up Phases.

Time frame:
30 days after last dose of study drug, continue up to 6 months
Reported as:
Count of participants · Participants
Number of Subjects With Adverse Events
ParticipantsA LONG-TERM SAFETY STUDY OF BRUTON'S TYROSINE KINASE (BTK) INH
Number of Subjects With Adverse Events199
SecondaryProgressive Disease (PD)

A progressive disease confirmed by a CT scan.

Time frame:
30 days after last dose of study drug, continue up to 6 months
Reported as:
Count of participants · Participants
Progressive Disease (PD)
ParticipantsIBRUTINIB/PCI-32765
Progressive Disease (PD)70
SecondaryDeath Event

All death events are due to AE, progressive disease, and other reasons.

Time frame:
30 days after last dose of study drug
Reported as:
Count of participants · Participants
Death Event
ParticipantsIBRUTINIB/PCI-32765
Death Event42
SecondaryDocumented Responses

Investigator-assessed responses were summarized descriptively for subjects with CLL/SLL and listed for subjects with other NHLs based on the efficacy population.

Time frame:
30 days after last dose of study drug, continue up to 6 months
Reported as:
Count of participants · Participants
Documented Responses
ParticipantsIBRUTINIB/PCI-32765
CLL/SLL180
Other NHL16
Treatment discontinuation3

Adverse events

Collected over 8 Years, 5 months. This is a safety longterm follow-up study, it doesn't have any common milestones.. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IBRUTINIB/PCI-32765111/199 (55.8%)111/199 (55.8%)114/199 (57.3%)
Most frequent serious events
Showing 10 of 171
Most frequent serious events
EventIBRUTINIB/PCI-32765
PneumoniaInfections and infestations32/199
Atrial fibrillationCardiac disorders21/199
CellulitisInfections and infestations13/199
SepsisInfections and infestations11/199
PyrexiaGeneral disorders8/199
Urinary tract infectionInfections and infestations6/199
Febrile neutropeniaBlood and lymphatic system disorders4/199
Acute kidney injuryRenal and urinary disorders4/199
DyspnoeaRespiratory, thoracic and mediastinal disorders4/199
Pleural effusionRespiratory, thoracic and mediastinal disorders4/199
Most frequent other events
Most frequent other events
EventIBRUTINIB/PCI-32765
HypertensionVascular disorders67/199
Lymphocyte count decreasedInvestigations24/199
NeutropeniaBlood and lymphatic system disorders21/199
Neutrophil Count decreasedInvestigations17/199
CataractEar and labyrinth disorders14/199
ThrombocytopeniaBlood and lymphatic system disorders10/199
HyperglycemiaMetabolism and nutrition disorders10/199
DiarroheaGastrointestinal disorders9/199
Upper Respiratory Track InfectionInfections and infestations9/199
White Blood cell count decreasedInvestigations8/199

Baseline characteristics

A total of 199 subjects were enrolled and received at least 1 dose of study treatment and therefore comprised the safety population which was used for safety analyses.

Age, Categorical
Age, Categorical(Participants)A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inh
<=18 years0
Between 18 and 65 years83
>=65 years116
Age, Continuous
Age, Continuous(Years)A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inh
Mean65.6 ± 8.98
Sex: Female, Male
Sex: Female, Male(Participants)A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inh
Female56
Male143
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inh
Hispanic or Latino6
Not Hispanic or Latino192
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inh
American Indian or Alaska Native1
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American8
White185
More than one race0
Unknown or Not Reported3
Region of Enrollment
Region of Enrollment(participants)A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inh
United States199
Estimated creatinine clearance rate (mL/min)
Estimated creatinine clearance rate (mL/min)(ML/min)A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inh
Mean85.55 ± 34.150
08

Study locations

16 sites
  • Stanford University
    Stanford, California 94305, United States
  • Stanford, California 94305, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Boston, Massachusetts 02215, United States
  • New Hyde Park, New York 11042, United States
  • New York, New York 10065, United States
  • Rochester, New York 14642-0001, United States
  • Columbus, Ohio 43210, United States
  • Springfield, Oregon 97477, United States
  • Nashville, Tennessee 37203, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Houston, Texas 77030, United States
  • Tyler, Texas 75702, United States
  • Fletcher Allen Health Care and University of Vermont
    Burlington, Vermont 05405, United States
  • Vancouver, Washington 98684, United States
  • Yakima Valley Memorial Hospital/North Star Lodge
    Yakima, Washington 98902, United States
09

References and documents

Publications

  • Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K, Sharman JP, Wierda W, Zhao W, Heerema NA, Luan Y, Liu EA, Dean JP, O'Brien S. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. Clin Cancer Res. 2020 Aug 1;26(15):3918-3927. doi: 10.1158/1078-0432.CCR-19-2856. Epub 2020 Mar 24. PubMed 32209572 ↗
  • Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019 Jun 25;3(12):1799-1807. doi: 10.1182/bloodadvances.2018028761. PubMed 31196847 ↗
  • O'Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, Sharman J, Wierda W, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chu AD, Byrd JC. Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood. 2018 Apr 26;131(17):1910-1919. doi: 10.1182/blood-2017-10-810044. Epub 2018 Feb 2. PubMed 29437592 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Apr 2019 and a completion of Apr 2019. It does not say whether these dates are actual or estimated.

Results were first posted in May 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2010
First posted
Apr 22, 2010
Start
Jun 2010
Primary completionActual
Apr 26, 2019
CompletionActual
Apr 26, 2019
Results first posted
May 7, 2020
Last update
May 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01109069
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Apr 22, 2010
Start date
Jun 2010
Primary completion
Apr 26, 2019
Completion
Apr 26, 2019
Results posted
May 7, 2020
Last update
May 27, 2020

Study contacts

James Dean, MD
study director · Medical Monitor

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion